News & Updates
Filter by Specialty:
Belimumab after rituximab reduces risk for severe flare in SLE
Treatment with belimumab following rituximab significantly lowers serum IgG anti-dsDNA antibody levels and the risk for severe flare in patients with systemic lupus erythematosus (SLE) that is refractory to conventional therapy, reveals a study.
Belimumab after rituximab reduces risk for severe flare in SLE
10 Nov 2021
Using wearables signals intent to improve health among individuals with mental illness
Among individuals living with depression and anxiety, the use of electronic wearable devices (EWDs) might be an indicator of their intent to lose weight and in turn may be valuable as a starting point for clinical interactions aimed at improving physical health, according to a recent study.
Using wearables signals intent to improve health among individuals with mental illness
10 Nov 2021
Eating fruits, exercising offer survival gains in diabetes
For patients with type 2 diabetes mellitus (T2DM), consumption of fruits and engagement in physical activity help cut the risk of death from all cause, cardiovascular disease (CVD), and stroke, as reported in a study.
Eating fruits, exercising offer survival gains in diabetes
10 Nov 2021
A3 adenosine receptor agonist safe, effective for treating NAFLD
Namodenoson, an A3 adenosine receptor (A3AR) agonist, shows clinical activity against nonalcoholic fatty liver disease (NAFLD) with or without nonalcoholic steatohepatitis (NASH), according to data from a phase II study.
A3 adenosine receptor agonist safe, effective for treating NAFLD
10 Nov 2021
Dose-reduced ARPI leads to inferior survival in CRPC patients
Reduced-dose treatment with androgen receptor pathway inhibitors (ARPI) lead to poorer oncological outcomes relative to full-dose regimens in castration-resistant prostate cancer (CRPC), a recent study has found.
